-
Nature Communications: Cholesterol transporters influence cancer development by regulating autophagy and mitochondria
Time of Update: 2022-11-25
Nature Communicationscholesterol transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics This study found that whether drugs to reduce cell membrane cholesterol levels or interfere with the expression of the GRAMD1C protein, it was possible to increase the level of autophagy in U2OS cells (human osteosarcoma cells).
-
Nature: For the first time, CRISPR is used to insert neoantigens into T cells to treat cancer, paving the way for personalized cancer treatment
Time of Update: 2022-11-25
The research team conducted clinical trials in 16 patients with solid tumors, including breast, lung, and colorectal cancers, which is also the first attempt to combine gene editing and T cell therapy, two hot areas of cancer treatment.
-
Conquest MYC: The light of day
Time of Update: 2022-11-25
For example, a small molecule inhibitor called MYCi975 can destroy MYC–MAX dimers, promote MYC degradation and kill cancer cells.
For example, a small molecule inhibitor called MYCi975 can destroy MYC–MAX dimers, promote MYC degradation and kill cancer cells.
-
PNAS: Professor Shao Zhimin's team draws a triple-negative breast cancer-specific transcript map to perfect the "Fudan tetratype"!
Time of Update: 2022-11-25
Breast cancer is the malignant tumor with the highest incidence in women, of which triple-negative breast cancer is the most "dangerous", accounting for about 15-20% of all breast cancers, and its ri
-
JAMA: Surgical weight loss can greatly reduce the risk of cancer incidence and death
Time of Update: 2022-11-25
Dr. Ali Aminian, the study's leader and director of the Institute for Weight Loss and Metabolism at Cleveland Clinic, said bariatric surgery is currently the most effective way to treat obesity.
-
Advanced cancer, treatment or abandonment? The result was too unexpected
Time of Update: 2022-11-25
” Due to the large number of people in the cancer hospital, Mr. Zhang was transferred to the Shanghai Meizhong Jiahe Cancer Clinic close to home, and Professor Zhang Xiaojian was in charge of treatment.
-
The most popular Metz open class TOP list in October is coming! Autumn is strong, and the knowledge of open classes is fruitful!
Time of Update: 2022-11-25
October suddenly passed, and the latest and hottest open class list was released! Which courses are the "favorites" of doctors in each department in October?Here, we have sorted out the most popular o
-
Safety issues: Another company withdrew its indication for PARP inhibitors
Time of Update: 2022-11-25
On November 11, GSK announced for the second time that it withdrew some indications of the PARP inhibitor Zejula, which will be used only in patients with ovarian cancer with harmful and suspected harmful germline BRCA mutations in the second line.
-
European Radiology: Radiomics in preoperative grading of pancreatic cancer
Time of Update: 2022-11-25
In this study, a diagnostic model including texture features was established, which could be used to predict the grade of PDAC, which provided support for preoperative, non-invasive and accurate clinical evaluation.
-
European Radiology: How can patient adherence to mammography screening be improved?
Time of Update: 2022-11-25
Plot: Density plot of compression parameters and discomfortThis study suggests that PAC mode, as an alternative method in the mammogram process, can enable screeners to achieve higher levels of compression, reduce breast thickness and radiation dose, and improve women's experience and compliance with mammography programs.
-
Trusso syndrome: 1 case
Time of Update: 2022-11-25
01PrefaceThe relationship between tumors and blood clots was first observed by Trousseau in 1865, hence the name Trousseau syndrome. Trusso syndrome is a paraneoplastic syndrome caused by hypercoagula
-
5 common medication misunderstandings you must know before targeted therapy!
Time of Update: 2022-11-25
[4] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM class="weui-dialog__ft"> UnCancel Allow： ， 。 ， ， In recent years, with the emergence of targeted therapy drugs, the treatment options of cancer patients are gradually increasing.
-
European Radiology: How to predict preoperative recurrence in hepatocellular carcinoma? The perfect combination of imaging and clinical
Time of Update: 2022-11-25
A study published today in the journal European Radiology established a recurrence risk score based on clinical parameters of HCC patients after preoperative EOB-MRI and liver resection, and compared it with postoperative scores and performance of four clinical staging systems.
-
Guidelines update Guidelines for Pharmacy Services for Antineoplastic Drugs
Time of Update: 2022-11-25
Summary Antibody drugs are drugs prepared by using antibody engineering technology mainly based on cell and genetic engineering technology, and are widely used in the treatment of malignant tumors. A
-
Yang Shengyong's team at Sichuan University discovered effective selective RIPK1 inhibitors through deep learning
Time of Update: 2022-11-25
On November 12, 2022, Shengyong Yang's team from Sichuan University published a report entitled "Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor" in Nature Communications The study proposes a generative deep learning (GDL) model, a distributed learning conditional recurrent neural network (cRNN) for generating a tailored library of virtual compounds for a given biological target.
-
Lung Cancer Concern Month Science Popularization (1) What is the burden of lung cancer?
Time of Update: 2022-11-25
2 JAMA sub-journal: In 2019, the global lung cancer burden ranked first among men and second in women Globally, in the past decade from 2010 to 2019, the incidence of TBL (trachea, bronchial and lung cancer) jumped from the original third place to the second place; Of the total cancer burden, TBL was the leading cause of cancer death (18.
-
European Radiology； How can imaging be used to predict the ATRX mutation status of low-grade gliomas?
Time of Update: 2022-11-25
d, e model [18F]FDG PET+CE-T1WI+ADC ROC curves in the training and test groups In this study, a multicenter clinical radiology comprehensive model based on [18F]FDG PET and multimodal MRI was established, which can simultaneously provide structural, functional, and metabolic information and can be applied to predict the ATRX mutation status of IDH-mutated LGG.
-
7 strategies to improve oral bioavailability of PROTAC drugs
Time of Update: 2022-11-25
The high molecular weight of PROTAC (typically between 700-1200 Da), poor solubility, and low permeability pose challenges to improve oral bioavailability in vivo.
The high molecular weight of PROTAC (typically between 700-1200 Da), poor solubility, and low permeability pose challenges to improve oral bioavailability in vivo.
-
K drug was approved for the tenth indication, and immunotherapy drugs for the treatment of early triple-negative breast cancer were approved in China
Time of Update: 2022-11-25
Breakthrough therapies break the therapeutic dilemma and immunotherapy significantly improves patient survivalThe approval of the new indication is based on data from the Phase III clinical trial KEYNOTE-522, a randomized, double-blind, placebo-controlled, III study A phase clinical trial to evaluate the efficacy of pembrolizumab in combination with chemotherapy for neoadjuvant therapy and subsequent pembrolizumab monotherapy for adjuvant therapy, versus chemotherapy for neoadjuvant therapy and subsequent placebo for adjuvant therapy in patients with early-stage high-risk triple-negative breast cancer.
-
Small cell lung cancer, a competition of treatment options at home and abroad (2023.2 version)
Time of Update: 2022-11-25
NCCNClinical Practice Guidelines for Non-Small Cell Lung Cancer 2022. 5 (Chinese) (1), (2). NCCNSmall Cell Lung Cancer Clinical Practice Guidelines 2023. 2 (Chinese)CSCOGuidelines for the diagnosis a
